FDA's Pazdur encourages Chinese companies to bring low-cost PD-1 drugs to U.S. market

Richard Pazdur, director of FDA’s Oncology Center of Excellence, is urging Chinese companies to bring PD-1/PD-L1 inhibitors to the U.S. market and undercut the prices charged by multinational pharmas.

Chinese companies competing in the U.S. on the price of PD-1s “could potentially be a great thing for everyone because we haven’t seen the major western pharmaceutical companies moving on price,” Pazdur said at the American

Read the full 644 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE